Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.